Source-grounded facts extracted from QHSLab, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
QHSLab, Inc. issued 1,568,432 shares of common stock to MedScience Research Group, Inc. for cancellation of indebtedness.
“the Company issued an aggregate of 1,568,432 shares of its common stock, par value $0.0001 per share (the “Shares”), as directed by MedScience”
QHSLab, Inc. terminated Repurchase Agreement with MedScience Research Group, Inc..
“QHSLab, Inc. (the “Company”) consummated a Note Repurchase Agreement (the “Repurchase Agreement”) with MedScience Research Group, Inc., a Florida corporation (“MedScience”).”
QHSLab, Inc. issued 421,827 shares of common stock to Alex Mirakian MD PA for conversion of $126,548 of principal and accrued interest at $0.30 per share.
“the Company issued 421,827 shares of its common stock to Alex Mirakian MD PA in exchange for the conversion of $126,548 of principal and accrued interest under the Original Note. The shares were issued at an effective price of $0.30 per share.”
QHSLab, Inc. amended Promissory Note Modification and Partial Conversion Agreement with Alex Mirakian MD PA (effective 2025-12-31).
“On December 31, 2025, QHSLab, Inc., (the Company), entered into a Promissory Note Modification and Partial Conversion Agreement (the Modification Agreement) with Alex Mirakian MD PA (the Holder), in connection with a previously issued convertible promissory note dated May 7, 2021 (the Original Note).”
QHSLab, Inc. issued 416,666 warrants of warrant to two accredited investors for nil.
“The shares of common stock and warrants were offered and sold in a private placement to two accredited investors without general solicitation in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder.”
QHSLab, Inc. issued 1,666,663 shares of common stock of common stock to two accredited investors for $0.30 per share.
“$495,000. Pursuant to the subscription agreements, the Company issued an aggregate of 1,666,663 shares of common stock, par value $0.0001 per share, at a purchase price of $0.30 per share, together with an aggregate of 416,666 warrants to purchase shares of common stock. Each warrant is exercisable at an exercise price of $0.60 per share and expires on”
QHSLab, Inc. entered into Subscription Agreements with two accredited investors valued at approximately $500,000 (effective 2025-12-26).
“On December 26, 2025, QHSLab, Inc. (the “Company”) accepted subscription agreements from two accredited investors for the purchase of approximately $500,000 of the Company’s common stock and warrants”
QHSLab, Inc. reported a default on convertible notes of in excess of $1.4 million at 18 percent per annum.
“The Notes, which had been in default and bore interest at a default rate of 18 percent per annum, had an aggregate outstanding balance consisting of principal and accrued interest in excess of $1.4 million as of the date of redemption.”
QHSLab, Inc. faced acceleration on convertible notes of $1,400,853.77 with Mercer Street Global Opportunity Fund, LLC at 18% maturing August 10, 2022 and July 22, 2023.
“the default notice, according to the Lender, based upon an interest rate of 18% from the initial days of the defaults, the principal and accrued interest owed by the Company is $1,400,853.77, absent an additional 20% in default principal Lender claims it may demand. The Company believes this number is incorrect and will seek to resolve the discrepancy with the”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.